Sugi Predict

Sugi Predict / Compounds / SCHEMBL4675699

SCHEMBL4675699

SCHEMBL4675699

CC(C)(Br)C(=O)Nc1cccc(Br)c1O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 5/20 0.50
▸ PDK2 Q15119 5/20 0.50
▸ PDK3 Q15120 5/20 0.50
▸ PDK4 Q16654 5/20 0.50
▸ CXCR1 P25024 7/20 0.41
▸ CXCR2 P25025 7/20 0.41
▸ CETP P11597 1/20 0.40
▸ LMNA P02545 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ HTT P42858 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797039 1.00 PDK1 (0.50) PDK1PDK2PDK3PDK4CXCR1
SCHEMBL30659480 0.84 PDK1 (0.46) PDK1PDK2PDK3PDK4CXCR1
SCHEMBL19280535 0.84 PDK1 (0.68) PDK1PDK2PDK3PDK4CXCR1
SCHEMBL1161653 0.83 PDK1 (0.50) PDK1PDK2PDK3PDK4CXCR1
SCHEMBL31381671 0.81 PDK1 (0.53) PDK1PDK2PDK3PDK4CETP
SCHEMBL14302363 0.81 CETP (0.39) PDK1PDK2PDK3PDK4CETP
SCHEMBL23705971 0.80 RXFP1 (0.51) CXCR1CXCR2POLBMEN1NPC1
SCHEMBL8023112 0.79 CETP (0.53) PDK1PDK2PDK3PDK4CETP
SCHEMBL4969113 0.79 LMNA (0.48) PDK1PDK2PDK3PDK4CETP
SCHEMBL14243354 0.79 NPC1 (0.46) PDK1PDK2PDK3PDK4CXCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 — — US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 — — US disclosed
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders C4 THERAPEUTICS, INC. (US) 2025-09-23 — — US disclosed
US-20250121070-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2025-04-17 — — US disclosed
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-04-17 — — US disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
EP-3083559-B1 THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2021-03-10 — — EP disclosed
US-9822107-B2 Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-21 — — US disclosed
US-7202241-B2 Benzoxazine derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-04-10 — — US disclosed
CN-1890227-A Benzoxazine derivatives and uses thereof HOFFMANN LA ROCHE (CH) 2007-01-03 — — CN disclosed
US-7141562-B2 Substituted benzoxazinones and uses thereof ROCHE PALO ALTO LLC (US) 2006-11-28 — — US disclosed
EP-1694656-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 — — EP disclosed
CN-1723205-A Substituted benzoxazinones and uses thereof HOFFMANN LA ROCHE (CH) 2006-01-18 — — CN disclosed
EP-1562918-A1 SUBSTITUTED BENZOXAZINONES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2005-08-17 — — EP disclosed
WO-2005058847-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 — — WO disclosed
US-20050124613-A1 Benzoxazine derivatives and uses thereof ROCHE PALO ALTO LLC 2005-06-09 — — US disclosed
WO-2004041792-A1 SUBSTITUTED BENZOXAZINONES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2004-05-21 — — WO disclosed
US-20040092512-A1 Substituted benzoxazinones and uses thereof ROCHE PALO ALTO LLC 2004-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 PDK1 2864/4885PDK2 2244/4885PDK3 2235/4885
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 PDK1 2864/4885PDK2 2244/4885PDK3 2235/4885
US-20250121070-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 SMARCA2, SMARCE1, SMARCA1 PDK1 4217/4885PDK2 2912/4885PDK3 3978/4885
US-20050124613-A1 Benzoxazine derivatives and uses thereof XDH, CYP4X1, CYP2C9 PDK1 461/4885PDK2 395/4885PDK3 391/4885
US-20040092512-A1 Substituted benzoxazinones and uses thereof CYP4X1, CYP3A5, CYP2D6 PDK1 1710/4885PDK2 976/4885PDK3 858/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 PDK1 2864/4885PDK2 2244/4885PDK3 2235/4885
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders CRBN, STUB1, CUL1 PDK1 2864/4885PDK2 2244/4885PDK3 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.